Navigation Links
Aprea to Present Phase I/II Trial Design
Date:5/18/2010

STOCKHOLM, May 18, 2010 /PRNewswire/ -- Among more than 5000 poster abstracts, Aprea AB has been selected to present a poster at the annual American Society of Clinical Oncology (ASCO) Meeting in Chicago. The presentation will describe the scientific rational and design of the ongoing phase I/II clinical trial with Aprea's drug candidate APR-246.

Aprea's drug candidate APR-246 belongs to a new class of anticancer compounds shown to induce programmed cell death through a p53 mediated mode of action. The compound is currently being tested in a phase I/II clinical trial at seven clinics in Sweden. The study will include approximately 24 patients, and is an open labeled, dose-escalating study on mainly blood cancer patients, but also patients with prostate cancer.

"We are currently initiating the commercialization process and seeking partners. Therefore, it will be very interesting to have the opportunity to present and discuss the clinical study design of this totally new concept of treating cancer", says Charlotta Liljebris, Head of Development at Aprea AB.

To the editors

About Aprea

Aprea AB is a Swedish biotech company founded in 2003 and based on research performed at the Karolinska Institutet, Stockholm, Sweden. The company focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aberrations in p53 are common in many various cancer forms and are associated with increased resistance to standard chemotherapy and thus poor prognosis. Aprea is a Karolinska Development AB (publ) portfolio company. The other main owners are Industrifonden, Ostersjostiftelsen and Praktikerinvest.

About APR-246

APR-246 has been developed based upon results from researcher at the Karolinska Institute. The researchers have discovered that the substance is more efficacious in cancer cells than normal cells, which indicates it could produce significantly fewer side effects than conventional cancer treatments. By inducing the protein p53 the compound makes sure that the cellular suicide program is activated to eliminate the cancer cells. This has been shown in laboratories and animal studies with good results. A unique characteristic of the substance is that it can activate p53 even when the gene is inactivated due to a mutation. Cancers with mutated p53 are often resistant to conventional treatment.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

For more formation, please contact:

Thomas Uhlin, CEO Aprea AB, +46-705-335-137, e-mail: thomas.uhlin@aprea.com

Charlotta Liljebris, VP Development Aprea AB, +46-703-391-534, charlotta.liljebris@aprea.com

http://www.aprea.com


'/>"/>
SOURCE Karolinska Development and Aprea
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
2. Avicena Group to Present at Noble Financial Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CEL-SCI to Present at the Noble Financial Conference
7. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
8. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
9. Strategic Diagnostics Updates Roth Conference Presentation Time
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... , ... September 21, 2017 , ... ... clinical research sector professionals, has announced the addition of 5 new courses to ... - Compliance with Regulation 21 CFR Part 11 on Electronic Records and ...
(Date:9/21/2017)... New Haven, CT (PRWEB) , ... September 21, ... ... company developing bioresorbable scaffold technology, today announced the election of Paul Hermes, Entrepreneur ... Board of Directors. , Biorez has developed a proprietary, tissue-engineered scaffold for ...
(Date:9/20/2017)... ... September 20, 2017 , ... Diversity focused business accelerator, ... the Growth pitch competition to uncover the top technology-driven, women-led startups in Boston, MA, ... part of each city’s entrepreneurial events going on that week – in Boston, it ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... of a study examining the effects of exoskeleton-assisted walking on gait parameters ... (SCI). The article, "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):